Adeza to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
30 Octubre 2006 - 3:00AM
Business Wire
Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson,
president and chief executive officer, will make an investment
community presentation at the Rodman & Renshaw 8th Annual
Healthcare Conference on Tuesday, November 7 at 12:45 p.m. Eastern
time (9:45 a.m. Pacific time). The conference is being held at the
Palace Hotel, New York. A live audio and slide presentation will be
available via the Internet by visiting the Investor Relations
section of the company�s Web site at www.adeza.com. An archive of
the presentation will be available on the Web site for 14 days. For
more information about this conference visit
http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf19. About
Adeza Adeza designs, manufactures and markets innovative products
for women's health. Adeza's initial focus is on reproductive
healthcare using its proprietary technologies to predict preterm
birth and assess infertility. Adeza's principal product is a
patented diagnostic test, FullTerm, The Fetal Fibronectin Test,
which utilizes a single-use, disposable cassette and is analyzed on
Adeza's patented TLiIQ� System. This product is approved by the
U.S. Food and Drug Administration (FDA) for use in assessing the
risk of preterm birth. Adeza also markets and sells the E-tegrity�
Test, an infertility-related test to assess receptivity of the
uterus to embryo implantation in women with unexplained
infertility. In May 2006, Adeza announced the submission of its New
Drug Application (NDA) to the FDA for Gestiva, a long-acting form
of a naturally occurring progesterone to prevent preterm birth in
women with a history of preterm delivery. On October 23, 2006 Adeza
announced that it received an approvable letter from the FDA,
subject to the completion of certain animal studies and other
conditions. More information is available at www.adeza.com. Adeza
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements, including for example, statements about the uses of
Adeza�s products and potential regulatory approvals. The inclusion
of forward-looking statements should not be regarded as a
representation by Adeza that any of its plans will be achieved.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in Adeza's
business including, without limitation, risks related to obtaining
and maintaining government approvals of our products. Further
information about these and other risks is included Adeza�s Annual
Report on Form 10-K and other periodic and current reports filed by
Adeza with the Securities Exchange Commission, which are available
from the SEC's Web site (www.sec.gov), and also available on the
Investor Relations section of Adeza�s Web site. All forward-looking
statements are qualified in their entirety by this cautionary
statement and Adeza undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof. Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson,
president and chief executive officer, will make an investment
community presentation at the Rodman & Renshaw 8th Annual
Healthcare Conference on Tuesday, November 7 at 12:45 p.m. Eastern
time (9:45 a.m. Pacific time). The conference is being held at the
Palace Hotel, New York. A live audio and slide presentation will be
available via the Internet by visiting the Investor Relations
section of the company's Web site at www.adeza.com. An archive of
the presentation will be available on the Web site for 14 days. For
more information about this conference visit
http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf19. About
Adeza Adeza designs, manufactures and markets innovative products
for women's health. Adeza's initial focus is on reproductive
healthcare using its proprietary technologies to predict preterm
birth and assess infertility. Adeza's principal product is a
patented diagnostic test, FullTerm, The Fetal Fibronectin Test,
which utilizes a single-use, disposable cassette and is analyzed on
Adeza's patented TLiIQ(R) System. This product is approved by the
U.S. Food and Drug Administration (FDA) for use in assessing the
risk of preterm birth. Adeza also markets and sells the
E-tegrity(R) Test, an infertility-related test to assess
receptivity of the uterus to embryo implantation in women with
unexplained infertility. In May 2006, Adeza announced the
submission of its New Drug Application (NDA) to the FDA for
Gestiva, a long-acting form of a naturally occurring progesterone
to prevent preterm birth in women with a history of preterm
delivery. On October 23, 2006 Adeza announced that it received an
approvable letter from the FDA, subject to the completion of
certain animal studies and other conditions. More information is
available at www.adeza.com. Adeza cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements, including for
example, statements about the uses of Adeza's products and
potential regulatory approvals. The inclusion of forward-looking
statements should not be regarded as a representation by Adeza that
any of its plans will be achieved. Actual results may differ
materially from those set forth in this release due to the risks
and uncertainties inherent in Adeza's business including, without
limitation, risks related to obtaining and maintaining government
approvals of our products. Further information about these and
other risks is included Adeza's Annual Report on Form 10-K and
other periodic and current reports filed by Adeza with the
Securities Exchange Commission, which are available from the SEC's
Web site (www.sec.gov), and also available on the Investor
Relations section of Adeza's Web site. All forward-looking
statements are qualified in their entirety by this cautionary
statement and Adeza undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof.
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Adeza Biomedical (MM) (NASDAQ): 0 recent articles
Más de Adeza Artículos de Noticias